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Objective. To assess the long-term eﬀects of metformin in combination with lifestyle intervention and its association between
insulinlevelsandthedegreeofsteatosisatultrasonography(US)inobeseadolescents.Methods.Thirty-ﬁvepostpubertalobeseboys
were randomized into two groups: one receiving metformin in combination with a multidisciplinary lifestyle intervention versus
a placebo group, which also received the same intervention. The visceral, subcutaneous fat and degree of steatosis were measured
by ultrasonography. Fasting blood samples were collected to analyze glucose, insulin, insulin resistance, and aminotransferases.
Repeated ANOVA measures were used to compare changes over time and between groups, and Spearman’s correlations were used
to identify an association between insulin and the degree of steatosis at US. Results. There was a positive correlation between the
degree of steatosis at US with insulin concentrations and HOMA-IR. Long-term therapy plus metformin signiﬁcantly reduced
body weight, body mass index, insulin, HOMA-IR, and visceral fat. Conclusions.M e t f o r m i nw a sm o r ee ﬀective than the placebo
in improving clinical parameters associated with obesity and steatosis.
1.Introduction
Nonalcoholic Fatty Liver Disease (NAFLD) aﬀects 10% to
39% of the world population, 50% of diabetic patients,
57% to 74% of obese people, and up to 90% of the people
with morbid obesity. Its prevalence in obese adolescents is
between 22.5% and 52.8% [1, 2]. When not appropriately
treated, NAFLD can progress to cirrhosis [1, 2]. Thus,
treatmentofNAFLDisarelevantissueinclinicalhepatology,
and several therapeutic approaches have been tested in
uncontrolled and controlled pilot studies [3].
Obesity and type 2 diabetes are considered the most
powerful predisposing risk factors for the development of
severe manifestations of NAFLD [1]. It is important to note
that adipose tissue is recently considered endocrine organ
strictly related to several comorbidities. The expansion of
visceral fat is a determinant risk factor for the development
of NAFLD in obese individuals [4]. Moreover, a new study
reported that the extent of hepatic inﬂammation and ﬁbrosis
is augmented incrementally with increases in visceral fat.
For each 1% increase in visceral fat, the odds ratios for
increasing liver inﬂammation and ﬁbrosis were 2.4 and 3.5,
respectively. Visceral fat remained an independent predictor
of advanced steatohepatitis and ﬁbrosis even when the
model controlled for insulin resistance and hepatic steatosis
[5].2 Journal of Obesity
Considering the relation between obesity and NAFLD,
an adequate treatment must include strategies to reduce
all Metabolic Syndrome predictor factors, including gradual
bodymassreductionandeﬀortstocontrolbloodglucoseand
lipid levels [6]. A cornerstone of the strategy to treat obese
adolescents with NAFLD is a long-term multidisciplinary
intervention that utilizes exercise, clinical, psychological,
and nutritional therapies. Although an optimal management
program for NAFLD in obesity and insulin resistance has not
been established, some strategies are based on hypoglycemic
andtriglyceride-loweringagentsandonlifestyleintervention
through a low fat diet, vitamin E supplementation, and
exercise [7].
Metformin is a well-established oral hypoglycemic agent
in the treatment of adults with type 2 diabetes mellitus and
other conditions of insulin resistance. It acts by decreasing
hyperinsulinemia and improving hepatic insulin resistance
[8]. In pediatric obese patients with insulin resistance,
metformin has also been shown to promote weight loss [9,
10]. It was observed that short-term use of metformin is well
tolerated by obese children and that it has a beneﬁcial eﬀect
on Body Mass Index (BMI) and cardiovascular autonomic
control as well as a trend toward the improvement of insulin
sensitivity [11]. Thus, long-term treatment with metformin
may provide a means to ameliorate the metabolic proﬁle of
obese adolescents.
The role of metformin in the reduction of insulin resis-
tance and visceral in the pediatric NAFLD obese population
has not been adequately studied. Therefore, the main aim of
this study was to assess the eﬀect of metformin in obese ado-
lescents with NAFLD who participated in a multidisciplinary
lifestyle modiﬁcation program. Furthermore, it aimed to
identify the association between insulin resistance and the
degree of steatosis at US in obese patients.
2. Methods
2.1. Subjects. Obese adolescent boys were recruited for
this study from the Multidisciplinary Obesity Intervention
Program outpatient clinic of the Federal University of S˜ ao
Paulo—Paulista Medicine School—between January and
February of 2008. The boys included in the study were
between 15 and 19 years old, presented with primary
obesity (body mass index >95th percentile of the CDC
reference growth charts) [12], and had reached the initial
postpubertal Tanner stage ﬁve [13]. The initial cohort of
the present study that met the above criteria included
80 individuals. Subsequently, 35 obese boys who had a
positive ultrasound diagnosis of NAFLD were selected and
randomized into two groups: lifestyle modiﬁcation plus
metformin (n = 21) and lifestyle modiﬁcation plus placebo
(n = 14). The adolescents and their families signed an
agreement to participate, on a voluntary basis, in a long-
term multidisciplinary therapy. All subjects performed an
ergometric test before starting the program and had the
approval of a physician. The exclusion criteria were an
identiﬁed genetic disease, metabolic or endocrine disease,
chronic alcohol consumption (>20g/day) [14], and previous
drug utilization or other causes of chronic liver disease.
All patients had normal age-speciﬁc growth and sexual
development, and none had marked hirsutism or severe
acne.
This study was carried out in accordance with the
principles of the Helsinki declaration and was formally
approved by the Ethical Committee of the Federal University
of S˜ ao Paulo—Paulista Medicine School (no. 0135/04).
Informedconsentwasobtainedfromallsubjectsand/ortheir
parents.
2.2. Protocol. After being diagnosed with NAFLD diagnosis,
obese male adolescents were submitted to a long-term mul-
tidisciplinary therapy (12 months) that aimed at promoting
changes in their sedentary lifestyles and nutritional habits.
The basic requirement for participation was the motivation
to follow the therapy, presenting high attendance (>75%) at
the sessions.
The multidisciplinary therapy consisted of aerobic exer-
cise, nutritional, psychological assistance and clinical man-
agement of obesity, and NAFLD. The short-term inter-
vention corresponded to 6 months and the long-term
intervention to 12 months. This model of multidisciplinary
therapy was suggested by the World Health Organization
(WHO) [15]. This kind of treatment attempts a more
integrated overview of the key role of these emerging strate-
gies for therapeutic intervention. The program consisted of
four physicians, two dietitians, four physiologists, and one
psychologist.
Subjects were medically screened, had their pubertal
stage assessed, and had their anthropometrics proﬁle mea-
sured (height, weight, and body mass index). A blood
sample was collected and analyzed for glucose and insulin
concentrations, as well as alanine aminotransferase (ALT),
aspartateaminotransferase(AST),andgamaglutamilamino-
transferase (GGT). Ultrasound and ergometric tests were
performed.Thepatientswererandomizedtothemetformin-
treated group (500mg twice daily) according to Freemark
and Bursey [9] and to the placebo group. The results
were compared at baseline and after short- and long-term
interventions. To remove any inﬂuence of diurnal variations,
the procedures were scheduled for the same time of day and
at least 15 hours after the last training session. Thereafter,
all 35 obese male adolescents with a diagnosis of NAFLD
started the multidisciplinary long-term weight loss therapy.
Two placebo-treated subjects and four metformin-treated
subjects withdrew from the study within the ﬁrst 12 weeks
for reasons unrelated to drug toxicity or complications of the
trial. Their laboratory results were not included in the ﬁnal
analysis.
3. Measurements
3.1. Anthropometric Measurements and Body Composition.
Wearing light clothes and no shoes, subjects were weighed to
the nearest 0.1kg on a Filizola scale. Height was measured to
the nearest 0.5cm using a wall-mounted stadiometer (Sanny,
model ES 2030). BMI was calculated as body weight (kg)
divided by height (m) squared (kg/m2).Journal of Obesity 3
3.2. Serum Analysis. Blood samples were collected in the
outpatient clinic around 08:00h after an overnight fast.
Insulin resistance was assessed by the homeostasis model
assessment insulin resistance index (HOMA-IR). HOMA-IR
was calculated using the fasting blood glucose (FBG) and the
immunoreactive insulin (I): [FBG (mg/dl) × I (mU/l)]/405.
The HOMA-IR data were analyzed according to reference
values described by Schwimmer et al. [14].
3.3. Hepatic Steatosis and Measurements of Visceral and Sub-
cutaneous Adipose Tissues. All abdominal ultrasonographic
procedures and measurements of visceral and subcutaneous
fat tissue and fatty liver were performed before and after
the intervention in a double-blinded manner by the same
specialized physician. A 3.5MHz multifrequency transducer
(broad band) was used for the diagnosis. This procedure
permits a reduced margin of risk for misclassiﬁcation.
The intraexamination coeﬃcient of variation for US was
0.8%. This method was previously standardized for obese
adolescents [2, 4].
Ultrasonic measurements of intraabdominal, “visceral”,
and subcutaneous fat were taken. Ultrasound-determined
subcutaneousfatwasdeﬁnedasthedistancebetweentheskin
and external face of the rectoabdominal muscle. Visceral fat
was deﬁned as the distance between the internal face of the
same muscle and the anterior wall of the aorta [16].
The deﬁnition of ultrasonic fatty liver was based on
previously reported diagnostic criteria. Detected liver steato-
sis was classiﬁed as degree 1 (liver attenuation slightly less
than spleen), degree 2 (more pronounced diﬀerence between
liver and spleen and intrahepatic vessels not seen or slightly
higherattenuationthanliver),ordegree3(markedlyreduced
liver attenuation with sharp contrast between liver and
intrahepatic vessels) [17].
3.4. Clinical Therapy. The patients visited the endocrinolo-
gist once a month to record health and clinical parameters.
Medical followup included initial medical history, physical
examination, and appropriate tests following regular clinical
surveillance. The endocrinologist also evaluated the possible
collateral eﬀects of metformin use.
3.5. Nutritional Therapy. Energy intake was set at the
levels recommended by the dietary reference intake for
subjects with low levels of physical activity of the same
age and gender. They were encouraged to reduce their
food intake and follow a speciﬁcally balanced diet, reduc-
ing saturated fats and reﬁned sugars [18]. No drugs or
antioxidants were recommended. Once a week, adolescents
had a dietetics lesson (food pyramid, recordatory inquiry,
weight loss diets, dietetic versus low calorie foods, fat
and cholesterol, nutrition facts). Additionally, individual
nutritional counseling was recommended when patients had
problems making changes in their dietary consumption
[19].
At the beginning and after the long-term multidisci-
plinary therapy, each adolescent ﬁlled in a three-day dietary
record with the help of his/her parents. Portions were
measured in terms of familiar volume and size. The nutri-
tionist taught the parents and the adolescents how to record
food consumption. These dietary data were transferred to
a computer by the same nutritionist, and the nutrient
composition was analyzed by a PC program developed at the
Federal University of S˜ ao Paulo—Paulista Medicine School
(Nutwin software, for windows, 1.5 version, 2002) —based
on Western and local food tables. In addition, the parents
were encouraged to call if they needed further information.
3.6.ExerciseTherapy. Duringthemultidisciplinaryinterven-
tion, adolescents followed a personalized aerobic training
program comprised of 60-minute sessions, three times
a week (180 minutes/week) under the supervision of a
physiologist. The program was developed according to the
results of an initial oxygen uptake test for aerobic exercises
(cycle ergometer and treadmill). The intensity was set at
a workload corresponding to ventilatory threshold 1 (50%
to 70% of oxygen uptake test). After 6 weeks, aerobic
tests were performed to assess physical capacities and to
individually adjust physical training intensity. During the
aerobic sessions, the adolescents’ heart rate was continuously
monitored.TheexerciseprogramwasbasedontheAmerican
College of Sports Medicine Statement (2001) [20]. To assess
improvement in cardiovascular function, the subjects per-
formed the same exercise test protocol used at the beginning
of the study after 6 weeks and again at the end of the
short- and long-term therapies. The physiologists regularly
participated in the training sessions to encourage lifestyle
changes.
3.7. Psychological Therapy. Obesity has been associated with
several psychological problems, such as depression, distur-
bances in body image, anxiety, and a lowered self-esteem.
Validated questionnaires designed to assess these problems
were used to diagnose psychological problems in the study
participants. During the multidisciplinary intervention, the
adolescents had weekly psychological orientation group
sessions in which they discussed body image and alimentary
disorderssuchasbulimia,anorexianervosa,andbingeeating
and their signs, symptoms, and consequences for health.
The relation between feelings and food and more familiar
problems, such as alcoholism, and other topics were also
discussed. An individual psychological therapy program was
recommended when nutritional and behavioral alterations
were found.
4.DataAnalysis
All data were analyzed using STATISTICA version 6 for
Windows with the signiﬁcance level set at P<. 05. All
data were expressed as mean ± SD unless otherwise stated.
Distributional assumptions of quantitative variables were
veriﬁed by the Kolmogorov-Smirnov test. Comparisons
between groups and changes over time were made using
the ANOVA for repeated measures, followed by post hoc
comparison with a Tukey test. Spearman’s Correlations were
made to identify a possible association between insulin
resistance and the degree of steatosis at US in obese patients.4 Journal of Obesity
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Figure 1: Correlation between degree of steatosis at US and Insulin
levels at baseline conditions of adolescent obese boys.
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Figure 2: Correlation between degree of steatosis at US and
HOMA-IR at baseline conditions of adolescent obese boys.
5. Results
At baseline, all patients presented with degree I to II liver
steatosis. After long-term therapy, the prevalence of NAFLD
was decreased similarly in both groups, from 100% to 46.2%
and 50% for metformin-treated and placebo-treated groups,
respectively. Indeed, there was a positive correlation between
the degree of steatosis at US with insulin concentrations
(Spearman’s r = 0.45) and HOMA-IR (Spearman’s r = 0.48)
(Figures 1 and 2).
At baseline, the two groups did not diﬀer signiﬁcantly in
all measures analyzed. After short- and long-term therapies,
the metformin-treated group presented a signiﬁcant reduc-
tion in body weight, BMI, insulin concentration, HOMA-
IR, and visceral fat (P<. 05 measured by two-way ANOVA
for repeated measures). On the other hand, in the placebo-
treated group, the reduction in body weight and visceral fat
after long-term therapy was not signiﬁcant. The mean values
of serum hepatic transaminases did not show diﬀerences in
either group at any time point (Table 1).
After one year of multidisciplinary therapy, all patients
in the placebo group presented altered HOMA-IR (>2.0)
according to Schwimmer et al. criteria [14], and two of them
hadnormalizedALTenzymelevels.Indeed,inthemetformin
group, three individuals had normalized HOMA-IR, and ﬁve
had normalized ALT values.
6. Discussion
The pathogenesis of NAFLD is still not clear; however,
there is evidence that insulin resistance and visceral fat
play an important role in this disease [21]. According to
Park et al. [22], patients with central adiposity and insulin
resistance have a higher risk of NAFLD, reinforcing the
strict association between these two parameters. In fact,
i tw a so b s e r v e dt h a tb o t hg r o u p sa n a l y z e dh a da l t e r e d
HOMA-IR and insulin levels at baseline. Indeed, a positive
correlation between the degree of steatosis at US with insulin
concentrationsandHOMA-IRwasshown,corroboratingthe
ﬁndings of previous studies [21, 22] (Figures 1 and 2).
Given the close relations between the metabolic syn-
drome and NAFLD, an adequate treatment must be included
for all risk factors associated with obesity [23]. In this way,
metformin use can be an important strategy to control
insulin sensitivity in patients with NAFLD.
The mechanism by which metformin improves the
clinical parameters of NAFLD might involve the eﬀect of
the drug on the inhibition of intestinal glucose absorption,
on the reduction of hepatic glucose production, and on the
improvementofinsulinsensitivityinperipheraltargettissues
[24, 25].
In the present investigation, only the metformin-treated
group presented a signiﬁcant reduction in body mass, BMI,
insulin concentration, HOMA-IR, and visceral fat after
short- and long-term interventions (Table 1). Although we
did not observe a statistical decrease in all parameters
in the placebo group, this group did have a signiﬁcant
reduction in visceral fat tissue. These ﬁndings suggest that
multidisciplinary therapy in combination with metformin is
important to improve these variables, as well as ALT enzyme
levels, which are clearly correlated with the development of
NAFLD [26, 27].
Our data corroborated with those of Fu et al. [24],
suggesting that metformin therapy and lifestyle modiﬁcation
improve parameters indicative of Metabolic Syndrome and
NAFLD. A study with obese adolescents demonstrated
that insulin resistance and the associated compensatory
hyperinsulinemia are usually associated with obesity, and it
can be considered an initial factor of Metabolic Syndrome
development [28].
The eﬀects of metformin on NAFLD were recently
compared with a lipid and calorie-restricted diet in a 6-
month, open label, randomized study. The mean changes
in insulin, insulin resistance (HOMA-IR), and aminotrans-
ferase concentrations were greater in the experimental arm
than in the group given only dietary advice [29].
A previous randomized, controlled trial of metformin
in an obese pediatric population with insulin resistance
demonstrated that metformin therapy is safe and wellJournal of Obesity 5
Table 1: Characteristics of adolescent obese boys measured at baseline, 6 months, and 1 year after multidisciplinary lifestyle program
associated with metformin therapy.
Placebo group Metformin group
Basal 6 months 1 year Basal 6 months 1 year
BM (wt) 114.20 ±10.7 110.9 ±8.56 112.22 ± 5.68 105.42 ±8.00 98.65 ±9.37# 97.39 ±10.41
†
BMI (wt/ht2)3 7 .02 ±3.15 36.69 ±2.89 37.23 ±2.83 37.24 ±3.44 34.05 ±4.01# 34.39 ± 4.60
†
Glucose (mg/dl) 91.75 ±7.47 93.25 ±8.08 96 ±6.48 93.58 ±7.30 92.28 ±7.73 96 ±8.97
Insulin (μU/mL) 18.77 ±6.71 19.73 ±6.84 19.2 ±5.30 22.35 ±11.82 16.52 ±9.7# 15.83 ±10.34
†
HOMA-IR 4.28 ±1.66 4.53 ±1.56 4.57 ±1.39 5.23 ±3.13 .83 ±2.73# 3.81 ±2.62
†
Visceral (cm) 4.87 ±1.52 5.37 ±1.85 3.55 ±1.80 4.90 ±1.04 3.72 ±1.24# 4.00 ±1.07
†
Sub (cm) 3.29 ±0.83 3.20 ±0.87 3.46 ±0.08 3.17 ±0.60 2.86 ±0.74 2.69 ±0.96
AST(U/L) 28.37 ±14.38 26.75 ±9.40 33 ±16.71 33.52 ±10.13 26.78 ±6.80 28.77 ±11.99
ALT (U/L) 52.12 ±24.93 48.25 ±17.36 57.25 ±38.01 52.05 ±26.89 39.64 ±16.35 41.11 ±12.48
GGT (U/L) 27.62 ±7.19 28 ±5.70 24.25 ±7.50 33.52 ±6.69 29.35 ±10.35 31.44 ±14.37
ReferencenormalvaluestoGlucose(60–110mg/dL),Insulin(<20μU/mL),HOMA-IR(<2.0),AST(10–40U/L),ALT(10–35U/L),andGGT(17–30U/L)[14]
Placebo group versus Metformin group on the same occasion P ≤ .05 (ANOVA for repeated measures),
# Basal versus 6 months for the same group P ≤ .05 (ANOVA for repeated measures),
† Basal versus 1 year for the same group P ≤ .05 (ANOVA for repeated measures),
6 months versus 1 year for the same group P ≤ .05 (ANOVA for repeated measures).
BM (Body mass), BMI (Body Mass Index), HOMA-IR (homeostasis model assessment insulin resistance index), Sub (Subcutaneous adipose tissue), AST
(aspartate aminotransferase), ALT (alanine aminotransferase), and GGT (Gamma-glutamyl transferase).
tolerated. Indeed, the patients had improved insulin sensi-
tivity with metformin, similar to data veriﬁed in the present
investigation [18].
Other relevant ﬁndings in this study were that short-
term lifestyle intervention plus metformin was eﬃcient to
promote a signiﬁcant improvement in most of the param-
eters analyzed, and the long-term intervention improves
NAFLD control. Similar results were observed by Nadeau et
al. [30], suggesting that taking metformin in combination
with making lifestyle changes is important to NAFLD
management and that lifestyle improvement by itself may
n o tb ea se ﬀective. However, both treated groups showed an
important decrease in the prevalence of NAFLD.
A recent study indicates that metformin may have
antiinﬂammatory and lipolytic eﬀects mediated through
adipocytokines, suggesting that researchers should consider
these eﬀects in new studies [24]. Further clinical trial inves-
tigations involving a larger population, a placebo-control
group, a double-blind format, and a long-term followup of
metformin treatment are needed to improve our ﬁndings.
The lack of a histological endpoint is a limitation of this
study; however, we used the degree of steatosis observed at
US diagnosis and the hepatic transaminases as a noninvasive
score of liver damage in NAFLD.
In conclusion, taking metformin in combination with
lifestyle intervention was more eﬀective than intervention
alone to promote an improvement in insulin resistance,
visceral adiposity, and other commonly observed clinical
parameters.
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